Lymph node metastases in papillary thyroid cancer detected by quantitative real-time polymerase chain reaction for thyroglobulin and cytokeratine-19

Kaczka, Krzysztof; Fendler, Wojciech; Borowiec, Maciej; Młynarski, Wojciech; Celnik, Agnieszka; Pomorski, Lech

doi:10.5114/pjp.2013.36007

Cited by 6 publications

(9 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RAI and thyroid hormone suppression often complement the treatment plan. Although thyroid hormone suppression may decrease the incidence of disease recurrence and RAI may treat metastases, lymph node dissection (LND) is the typical therapeutic strategy for clinically evident cervical lymph node metastases [39, 40]. Specific inhibitors of the PI3K/Akt signalling pathway develops against several target molecules involved in this pathway may be important therapeutics for the treatment of thyroid cancer (inhibition of Akt phosphorylation using perifosine or inhibition of mTOR inhibition using temsirolimus) [41].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of PTEN, PI3K, MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinoma

Duman¹,

Kara²,

Uğuz³

et al. 2014

View full text Add to dashboard Cite

Aim of the studyImportant signalling pathways play fundamental roles in the pathogenesis of thyroid carcinoma (TC). PTEN, mTOR, PI3K-p85 and K-Ras are the principal factors involved in these signalling pathways. To immunohistochemically examine the expressions of PI3K, mTOR and PTEN in patients suffering from follicular TC, papillary TC or variants thereof, as well as to investigate KRAS mutations via PCR to determine their clinical and prognostic relevance to differentiated thyroid cancer.Material and methodsThe expression of PTEN, PI3K-p85 and mTOR was immunohistochemically examined, and the mutation of K-Ras was examined via PCR. The results obtained were compared to the clinico-pathologic characteristics of the patients.ResultsA significant correlation was found between p85 expression and lymphovascular invasions and between PTEN expression and multifocality (p = 0.048 and p = 0.04, respectively), and a correlation between p85 and capsular invasion was found, with a borderline statistical significance (p = 0.056). No expression of PTEN, p85 or Mtor was detected in normal tissue. K-Ras mutation was examined in 66 of the 101 patients (57.4%), and the percentage of patients exhibiting a K-Ras mutation was 17.4%. All of the patients exhibiting a K-Ras mutation were women (p = 0.047). The disease-free survival was 44.6 months (95% CI: 37.9–51.3) and was statistically significantly higher in the group that displayed level 1 or lower expression of p85 (p = 0.043).ConclusionsThe expression levels of the aforementioned markers were significantly higher in TC cells than in normal tissue. A significant correlation was detected between K-Ras mutation and gender. This study demonstrates that p85 and PTEN are markers that should be evaluated in further studies of TC.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of PTEN, PI3K, MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinoma

Duman¹,

Kara²,

Uğuz³

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Keratins 17 and 19 (K17 and K19) are type I keratins and their varying expression patterns have been implicated in cancer. Prognostic associations between K17 and K19 have been made for gastric adenocarcinoma, breast cancer, intraepithelial cervical cancer, ovarian cancer, hepatocellular carcinoma, and lung, larynx, thyroid,and oral cancer (Cohen-Kerem et al, 2004;Ikeda et al, 2008;Safadi et al, 2010;Ide et al, 2012;Kitamura et al, 2012;Alshareeda et al, 2013;Bugalho et al, 2013;Kaczka et al, 2013;Lee et al, 2013;Wang et al, 2013). In the present study, we evaluated the differential expression of K17 and K19 in tumoral and non-tumoral tissue.…”

Section: Introductionmentioning

confidence: 96%

Keratins 17 and 19 expression as prognostic markers in oral squamous cell carcinoma

Coelho¹,

Peterle²,

Santos³

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Five-year survival rates for oral squamous cell carcinoma (OSCC) are 30% and the mortality rate is 50%. Immunohistochemistry panels are used to evaluate proliferation, vascularization, apoptosis, HPV infection, and keratin expression, which are important markers of malignant progression. Keratins are a family of intermediate filaments predominantly expressed in epithelial cells and have an essential role in mechanical support and cytoskeleton formation, which is essential for the structural integrity and stability of the cell. In this study, we analyzed the expressions of keratins 17 and 19 (K17 and K19) by immunohistochemistry in tumoral and non-tumoral tissues from patients with OSCC. The results show that expression of these keratins is higher in tumor tissues compared to non-tumor tissues. Positive K17 expression correlates with lymph node metastasis and multivariate analysis confirmed this relationship, revealing a 6-fold increase in lymph node metastasis when K17 is expressed. We observed a correlation between K17 expression with disease-free survival and disease-specific death in patients who received surgery and radiotherapy. Multivariate analysis revealed that low expression of K17 was an independent marker for early disease relapse and disease-specific death in patients treated with surgery and radiotherapy, with an approximately 4-fold increased risk when compared to high K17 expression. Our results suggest a potential role for K17 and K19 expression profiles as tumor prognostic markers in OSCC patients.

show abstract

“…Cytokeratin 19 (CK19) was also reported to be highly expressed in the cytoplasm of PTC cells, − and the detection of CK19 expression in lymph nodes was recruited to estimate lymphatic metastasis of PTC. Therefore, axillary lymph nodes of mice in seven groups were collected and sectioned for CK19 staining (Figure ).…”

Section: Resultsmentioning

confidence: 99%

Charge Reversal Polypyrrole Nanocomplex-Mediated Gene Delivery and Photothermal Therapy for Effectively Treating Papillary Thyroid Cancer and Inhibiting Lymphatic Metastasis

Zhao²,

Chen

et al. 2022

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

As a traditional treatment for papillary thyroid cancer (PTC), surgical resection of diseased tissues often brings lots of inconveniences to patients, and the tumor recurrence and metastasis are difficult to avoid. Herein, we developed a gene and photothermal combined therapy nanosystem based on a polypyrrole (Ppy)–poly(ethylene imine)–siILK nanocomplex (PPRILK) to achieve minimally invasive ablation and lymphatic metastasis inhibition in PTC simultaneously. In this system, gelatin-stabilized Ppy mainly acted as a photothermal- and photoacoustic (PA)-responsive nanomaterial and contributed to its well-behaved photosensitivity in the near-infrared region. Moreover, gelatin-stabilized Ppy possessed a charge reversal function, facilitating the tight conjunction of siILK gene at physiological pH (7.35–7.45) and its automatic release into acidic lysosomes (pH 4.0–5.5); the proton sponge effect generated during this process further facilitated the escape of siILK from lysosomes to the cytoplasm and played its role in inhibiting PTC proliferation and lymphatic metastasis. With the guidance of fluorescence and PA bimodal imaging, gene delivery and Ppy location in tumor regions could be clearly observed. As a result, tumors were completely eradicated by photothermal therapy, and the recurrences and metastases were obviously restrained by siILK.

show abstract

Lymph node metastases in papillary thyroid cancer detected by quantitative real-time polymerase chain reaction for thyroglobulin and cytokeratine-19

Cited by 6 publications

References 32 publications

Evaluation of PTEN, PI3K, MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinoma

Evaluation of PTEN, PI3K, MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinoma

Keratins 17 and 19 expression as prognostic markers in oral squamous cell carcinoma

Charge Reversal Polypyrrole Nanocomplex-Mediated Gene Delivery and Photothermal Therapy for Effectively Treating Papillary Thyroid Cancer and Inhibiting Lymphatic Metastasis

Contact Info

Product

Resources

About